Status:
RECRUITING
Introduction of Y90-PET-CT Post Radioembolisation Therapy Scans
Lead Sponsor:
The Christie NHS Foundation Trust
Conditions:
Cancer
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Yttrium-90, attached to microspheres, usually referred to as 90Y-microspheres or Y-90 radioembolisation, can be used in some cases to treat patients with liver tumours or liver metastasis. The treatme...
Detailed Description
The study will be conducted on patients with liver cancer and/or liver metastasis, referred to as 90Y-microspheres radiation therapy or Y-90 radioembolisation. There will be 10 patients recruited. No ...
Eligibility Criteria
Inclusion
- Patients undergoing liver treatment Y90-Microspheres therapy.
- Male or female
- Aged 18-85 years
Exclusion
- A participant will not be eligible for inclusion in this study if any of the following criteria apply:
- History of, or suffers from, claustrophobia or participant feels unable to lie flat and still on their back for a period of up to 45 minutes in the scanner;
- o Priority will be given to their current clinical care scan Y-90-bremsstrahlung-SPECT
- In the opinion of the clinical team, they are unlikely to comply with the study protocol and restrictions that it imposes (i.e. patient uncomfortable to withstand a double scan on the day); Female participants of childbearing potential must confirm they are not pregnant (a strict requisite before 90Y-therapy anyway).
Key Trial Info
Start Date :
October 9 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2026
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06123676
Start Date
October 9 2023
End Date
May 1 2026
Last Update
November 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Christie NHS - Nuclear Medicine Department
Manchester, United Kingdom, M204BX